Nadia Soledad Alegre, Cecilia Claudia Garcia, Luis Ariel Billordo, Beatriz Ameigeiras, Daniel Poncino, Javier Benavides, Luis Colombato, Alejandra Claudia Cherñavsky
Clin Mol Hepatol 2020;26(2):216-226. Published online December 5, 2019
Background/Aims Toll-like receptors (TLRs) modulate T cell responses in diverse diseases. Co-stimulation of T cell activation via TLR9 induces production of interferon gamma (IFN-γ), priming of which is critical for differentiation of pro-inflammatory macrophages. These macrophages have a crucial role in nonalcoholic fatty liver disease (NAFLD). We aimed to evaluate the expression of TLR9 protein on T cells and the consequences of TLR9-mediated triggering of these cells in patients with NAFLD.
Methods Our study included 34 patients with simple steatosis, 34 patients with nonalcoholic steatohepatitis, eight patients with NAFLD who met general diagnostic criteria but lacked histological diagnosis, and 51 control subjects. We used a synthetic TLR9 ligand to co-stimulate T cells. We measured TLR9 expression in liver and peripheral T cells and CD69 and IFN-γ as phenotypic markers of T cell activation and differentiation by flow cytometry.
Results TLR9 expression on liver and peripheral T cells was lowest in patients with simple steatosis and was positively associated with anthropometric, biochemical, and histopathological features of NAFLD. In vitro co-stimulation of T cells from patients with simple steatosis induced a limited number of IFN-γ-producing CD8+ T cells. At baseline, these patients showed a low frequency of circulating type 1 CD8+ cells.
Conclusions The positive associations between TLR9 and anthropometric, clinical, and histological features and the crucial role of IFN-γ-in NAFLD suggest that limited TLR9 expression and production of IFN-γ play a protective role in patients with simple steatosis.
Citations
Citations to this article as recorded by
DNA sensors in metabolic and cardiovascular diseases: Molecular mechanisms and therapeutic prospects Hyosang Kwak, Ein Lee, Rajendra Karki Immunological Reviews.2025;[Epub] CrossRef
Macronutrient Modulation in Metabolic Dysfunction-Associated Steatotic Liver Disease—the Molecular Role of Fatty Acids compared with Sugars in Human Metabolism and Disease Progression Sinéad M Mullin, Aidan J Kelly, Méabh B Ní Chathail, Suzanne Norris, Christopher E Shannon, Helen M Roche Advances in Nutrition.2025; 16(3): 100375. CrossRef
Immune Landscape Changes in MASLD and the Effects of 11β‐HSD1 Inhibition Revealed by Single‐Cell Mass Cytometry Zayakhuu Gerelkhuu, Sehee Park, Yun Kim, Sang Won Lee, Dae Won Jun, Tae Hyun Yoon PROTEOMICS – Clinical Applications.2025;[Epub] CrossRef
Transcriptomic, Redox Status and Adipocytokine Profiles in Metabolic Dysfunction-Associated Steatotic Liver Disease: Impact of Coexisting Type 2 Diabetes Sanja Erceg, Ana Ninić, Jelena Kotur-Stevuljević, Omar Ben Mariem, Miloš Mitrović, Jelena Munjas, Miron Sopić, Boško Misita, Milica Mamić, Aleksandra Klisic, Ratko Tomašević Medical Sciences.2025; 13(4): 326. CrossRef
Gut microbiota in MAFLD: therapeutic and diagnostic implications Waleed Alghamdi, Mahmoud Mosli, Saleh A. Alqahtani Therapeutic Advances in Endocrinology and Metabolism.2024;[Epub] CrossRef
Role of pattern recognition receptors in the development of MASLD and potential therapeutic applications Lili Yu, Feifei Gao, Yaoxin Li, Dan Su, Liping Han, Yueming Li, Xuehan Zhang, Zhiwei Feng Biomedicine & Pharmacotherapy.2024; 175: 116724. CrossRef
Toll‐like receptors in health and disease Kunyu Wang, Hanyao Huang, Qi Zhan, Haoran Ding, Yi Li MedComm.2024;[Epub] CrossRef
Decoding the role of immune T cells: A new territory for improvement of metabolic‐associated fatty liver disease Jia Liu, Mingning Ding, Jinzhao Bai, Ranyi Luo, Runping Liu, Jiaorong Qu, Xiaojiaoyang Li iMeta.2023;[Epub] CrossRef
Overview of Cellular and Soluble Mediators in Systemic Inflammation Associated with Non-Alcoholic Fatty Liver Disease Patrice Marques, Vera Francisco, Laura Martínez-Arenas, Ângela Carvalho-Gomes, Elena Domingo, Laura Piqueras, Marina Berenguer, Maria-Jesus Sanz International Journal of Molecular Sciences.2023; 24(3): 2313. CrossRef
Peripheral immune cells in NAFLD patients: A spyhole to disease progression Shuang-Zhe Lin, Jian-Gao Fan eBioMedicine.2022; 75: 103768. CrossRef
Toll-like receptors and metabolic (dysfunction)-associated fatty liver disease Shaghayegh Khanmohammadi, Mohammad Shafi Kuchay Pharmacological Research.2022; 185: 106507. CrossRef
Immune–metabolic interactions in homeostasis and the progression to NASH Joanne A. Hoogerland, Bart Staels, David Dombrowicz Trends in Endocrinology & Metabolism.2022; 33(10): 690. CrossRef
TLR9: A friend or a foe Mona M. Saber, Nada Monir, Azza S. Awad, Marwa E. Elsherbiny, Hala F. Zaki Life Sciences.2022; 307: 120874. CrossRef
TLR9 in MAFLD and NASH: At the Intersection of Inflammation and Metabolism Christopher R. Shepard Frontiers in Endocrinology.2021;[Epub] CrossRef
Serum milk fat globule-EGF factor 8 protein as a potential biomarker for metabolic syndrome Han Ah Lee, Jihwan Lim, Hyung Joon Joo, Young-Sun Lee, Young Kul Jung, Ji Hoon Kim, Hyunggin An, Hyung Joon Yim, Yoon Tae Jeen, Jong Eun Yeon, Do-Sun Lim, Kwan Soo Byun, Yeon Seok Seo Clinical and Molecular Hepatology.2021; 27(3): 463. CrossRef
Toll-like receptor 1 as a possible target in non-alcoholic fatty liver disease Anja Baumann, Anika Nier, Angélica Hernández-Arriaga, Annette Brandt, Maria J. Lorenzo Pisarello, Cheng J. Jin, Esther Pilar, Amélia Camarinha-Silva, Jörn M. Schattenberg, Ina Bergheim Scientific Reports.2021;[Epub] CrossRef
Does limited expression of toll-like receptor 9 actually contribute to T cell activation and liver damage in nonalcoholic steatohepatitis? Hyuk Soo Eun Clinical and Molecular Hepatology.2020; 26(2): 236. CrossRef
Limited expression of toll-like receptor 9 on T cells and its functional consequences in patients with nonalcoholic fatty liver disease Jung Hwan Yu Clinical and Molecular Hepatology.2020; 26(2): 240. CrossRef
Toll-like receptor 9, a possible blocker of non-alcoholic steatohepatitis? Soung Won Jeong Clinical and Molecular Hepatology.2020; 26(2): 185. CrossRef
First
Prev
